Boston University

Sequenom, Inc.

Genelabs Technologies, Inc.

Clarapath, Inc.

University of California

Columbia University

The Chinese University of Hong Kong

Other

US Government As Represented by the Secretary of the Army

Agena Biosciences, Inc.

Univ. of Mass. Medical Center

Charles Cantor

Takeshi Sano

Cassandra L Smith

Chunming Ding

Cynthia A Edwards

Beth M Andrews

Partha Pratim Mitra

Kirk E Fry

Baris Yagci

Hubert Köster

Lisa M Turin

Hubert K&ouml;ster

Daniel P Little

Cong Zhang

Steven Smith

David Kleinfeld

Maryanne J O'Donnell-Maloney

Kwan Chee Chan

Yuk Ming Dennis Lo

Przemyslaw Szafranski

Mathias Ehrich

David L Kaplan

David Charles Schwartz

Grace DeSantis

Wai Kwun Rossa Chiu

Charlene M Mello

Reinhold Mueller

Jerry R Pinto

Christof M Niemeyer

Fouad A Siddiqi

James Joseph Collins

Alexander N Glazer

Thomas Becker

Kenneth A Marx

Mary Rusckowski

Janak Sewkarran

Donald J Hnatowich

Farren J Isaacs

Doris B Tse

Robert Shusko

Sandor Vajda

Dong-Jing Fu

Daniel J Dwyer

Natalia E Broude

Gabriel O Reznik

Roy S Chuck

Marek Przetakiewicz

Rossa Wai Kwun Chiu

Yuk-Ming Dennis Lo

Young Tae Kim

Cosmin Deciu

Gary Olson

Dirk Johannes Van Den Boom

Richard L Edelson

Christopher Self

Zeljko Dzakula

Richard Axel

Andreas Braun

Hubert Koster

Sung Kyun Kim

Takashi Ito

Charles Michael Cook

Francis P Gasparro

David M Lough

Anson Hatch

Bo Yin Tsui

Susan S Taylor

Stefan M Kammerer

Mark W Pandori

Wilma A Saffran

Wai Kwon Rossa Chiu

Ron Yaar

John T Welsh

Lora Burns-Hamuro

Carlos Argarana

Jonathan Gardi

Dmitry Khavulya

Lex H Van Der Ploeg

Marek Prezetakiewiczr

Carlos Witte-Hoffmann

John Misasi

Chandran R Sabanayagam

Guobing Xiang

Maryanne J Little

Young-Soo Kwon

Changwon Kang

Carlos Witte-Hoffman

Suzanne H Giannini

Rossa Wai Chiu

Partha P Mitra

Rossa Wai-Kwun Chiu

A composition of the present disclosure includes an aqueous dispersion of epoxy resin particles. The epoxy resin particles include at least two 1,2-epoxide groups. The composition further includes one or more anti-adhesive agents, one or more anti-microbial agents, or a combination of one or more anti-adhesive agents and one or more anti-microbial agents.

Epoxy-siloxane copolymer compositions and methods of making and using the same

Improved solid supports and methods for analyzing target nucleotide sequences are provided herein. Certain improvements are directed to efficiently preparing nucleic acids that comprise nucleotide sequences identical to or substantially identical to one or more target nucleotide sequences, or complement thereof. The prepared nucleic acids include a reference sequence that facilitates sequence analysis. The solid supports and methods provided herein minimize the number of steps required by published sequence analysis methodologies, and thereby offer improved sequence analysis efficiency.

Compositions containing identifier sequences on solid supports for nucleic acid sequence analysis

Systems and methods enable fully automated tissue processing using tissue processing components for producing tissue sections from a tissue sample block and to transfer the tissue sections to slides. A control device queries a Laboratory Information Management System (LIMS) with a sample identifier associated with the tissue sample block and receives tissue sample data from the LIMS. The control device generates tissue processing workflow parameters based on the tissue sample data for each tissue processing component to perform an automated tissue processing workflow. The control device automatically controls each tissue processing component according to the tissue processing workflow parameters to process the tissue sample block. The control device generates a block processing update message while the tissue sample block is processed and communicates the block processing update message to the LIMS to enable the LIMS to track the automated tissue processing workflow for the tissue sample block.

Connected systems for automated tissue section preparation and methods of use thereof

The present disclosure relates to systems and methods for facing a tissue block. In some embodiments, a method is provided for facing a tissue block that includes imaging a tissue block to generate imaging data of the tissue block, the tissue block comprising a tissue sample embedded in an embedding material, estimating, based on the imaging data, a depth profile of the tissue block, wherein the depth profile comprises a thickness of the embedding material to be removed to expose the tissue sample to a pre-determined criteria, and removing the thickness of the embedding material to expose the tissue to the pre-determined criteria.

Facing and quality control in microtomy

There is provided a histology system that comprises a microtome configured to expose a face of a tissue block comprising a tissue sample embedded in an embedding material and remove one or more tissue sections from the sample, a hydration system configured to hydrate the tissue block by depositing a hydrating liquid on the face of the tissue block, and a transfer system configured to transfer the one or more tissue sections from the microtome to one or more slides. In some embodiments, the hydration system is configured to produce droplet condensation of the hydrating liquid and deposit the condensation on the face of the tissue block.

Enhanced hydration methods and systems for histology

A system for optical interrogation of tissue samples, the system including: a microtome configured to section one or more tissue sections from a tissue block, the one or more tissue sections including one or more tissue samples; a transfer medium configured to gather the one or more tissue sections and to transfer the one or more tissue sections to one or more slides; and an optical interrogation system including an illumination system configured to illuminate the one or more tissue sections and an imaging system configured to perform an imaging analysis on the one or more tissue sections illuminated with the illumination system.

Preliminary diagnoses of cut tissue sections

A histology system includes a microtome configured to produce a tissue section from a tissue block, where the tissue section includes a tissue sample, a transfer system including a transfer medium to transfer the tissue section to a slide, and a vision system. The vision system includes an illumination system configured to illuminate the tissue section on the transfer medium and an imaging system configured to create imaging data of the tissue section on the transfer medium illuminated by the illumination system. The histology system further includes a processor to receive the imaging data and perform one or more quality control analysis based on the imaging data, where the one or more analysis includes a comparative analysis of the tissue section on the transfer medium with at least one of the tissue section on the tissue block or the tissue section on the slide.

The present disclosure also relates to systems and methods for quality control in histology systems. In some embodiments, a method is provided that includes receiving a tissue block comprising a tissue sample embedded in an embedding material, imaging the tissue block to create a first imaging data of the tissue sample in a tissue section on the tissue block, removing the tissue section from the tissue block, the tissue section comprising a part of the tissue sample, imaging the tissue section to create a second imaging data of the tissue sample in the tissue section, and comparing the first imaging data to the second imaging data to confirm correspondence in the tissue sample in the first imaging data and the second imaging data based on one or more quality control parameters.

Systems and methods for identifying a de novo mutation in a genome of a fetus are provided. Methods may include identifying a location of each of a plurality of cell-free nucleic acid molecules using sequence reads. Methods may also include identifying a first sequence in the sequence reads at a first location that is not present in the maternal or paternal sequences. Methods may additionally include determining a first fractional concentration of the first sequence in the biological sample at the first location. Further, methods may include determining a second fractional concentration of a fetal-specific second sequence. The second sequence may be inherited by the fetus from the father at the second location. In addition, methods may include classifying the first sequence as a de novo mutation at the first location in a fetal genome of the fetus if the first and second fractional concentrations are about the same.

Identifying a de novo fetal mutation from a maternal biological sample

Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations.

Methods and processes for non-invasive assessment of genetic variations

Growing community of inventors

Del Mar, CA, United States of America

Charles Cantor